奥扎格雷治疗急性脑梗死的临床观察

目的: 观察奥扎格雷治疗急性脑梗死的临床疗效及其安全性.方法: 81例经临床脑CT和/或MRI扫描确诊为急性脑梗死患者,随机分成奥扎格雷治疗组40例和东菱克栓酶对照组41例,两组均于治疗前后2周作神经功能缺损评分,结合治疗后患者的病残程度评定临床疗效,同时作凝血功能、血小板聚集和血粘度等检测.结果: 总有效率为97.5%,与对照组相比无显著性差异(P>0.05),奥扎格雷对血小板聚集有显著抑制作用.结论: 静脉滴注奥扎格雷治疗急性脑梗死安全,有效.

A Clinic Observation of Ozagrel in Treatment of Patients with Acute Cerebral Infarction

Objective: To observe the clinical effect and safety of ozagrel in treatment of patients with acute cerebral infarction(ACF).Method: 81 patients with acute cerebral infarction diagnosed by clinic and brain scan (CT/MRI)were randomly divided into zagrel group and controlled group treated with batroxobin. The nervous dysfunction of grades and clotting function, platelet aggregation test (PAGT), and platelet adhesiveness test (PADT) in two groups were measured before treatment and 2 weeks after treatmnet, respectively. Result: The overall effective rate in ozagrel group was 97.5%, which had no significant difference compared with the controlled group,(P> 0.05). The study result showed that ozagrel had a significant inhibiting effect in platelet aggregation. Conclusion: It's safe and effective that ozagrel in the treatment of patients with acute cerebral infarction by intravenous infusion.